Results The mean intraocular pressure (lOP) of this group of patients was reduced from 57.9 ± 10.6 mmHg to 39.0 ± 10.9 mmHg at 15 min, 28.3 ± 9.1 mmHg at 30 min and 20.4 ± 9.0 mmHg at 60 min after ALPI. No complications were encountered. In 8 of the 10 patients the corneal oedema cleared 1 h after ALPI. In the remaining 2 patients the corneal oedema cleared 2 h after ALPI.
Conclusion Immediate limited ALPI, without
adjunctive systemic anti-glaucomatous medications, appeared to be effective and safe in controlling the lOP in treating acute PACG with a duration of attack"'; 48 h. It may be as effective as 360° ALPI, and therefore has a role in those patients in whom 360° treatment is not possible.
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Primary angle closure glaucoma (PACe) is characterised by an abrupt rise in the intraocular pressure (lOP) caused by iris apposition to the trabecular meshwork. The eye suffering from PAce has elevated lOP, a shallow peripheral anterior chamber and JIMMY S.M. LAI, CLEMENT c.Y. THAM, DENNIS S.c. LAM corneal oedema.1 Laser iridotomy is the treatment of choice when there is a component of pupillary block? However, when the eye is acutely inflamed and in the presence of corneal oedema, laser iridotomy may not be possible. Traditionally, treatment involves lowering the lOP with both systemic and topical medications, and subsequently relieving the pupillary block by laser peripheral iridotomy when the cornea is clear?
Systemic medications for PAce include intravenous or oral carbonic anhydrase inhibitors and hyperosmotic agents. Topical medications include pilocarpine and beta blockers.4 Systemic carbonic anhydrase inhibitors cause loss of appetite, paraesthesia and drowsiness in most patients. They can also cause potentially serious side effects, such as metabolic acidosis, Stevens-Johnson syndrome and blood dyscrasias.5--8 They are contraindicated in patients with hypokalaemia, hyponatraemia, renal and hepatic failure, sulphonamide sensitivity and pregnancy. Systemic hyperosmotic agents may also cause rare but potentially life-threatening complications such as electrolyte disturbance, pulmonary oedema and congestive heart failure, especially in patients with pre-existing cardiovascular diseases. 9 Systemic medications, together with topical anti-glaucomatous eyedrops, take time to act. They sometimes fail to control the lOP. If the lOP remains high, the definitive treatment of laser peripheral iridotomy may not be achievable because of corneal oedema, shallow anterior chamber, and thick iris resulting from the semi-dilated pupil.
Traditionally, argon laser peripheral iridoplasty (ALPI) has been used to open the appositionally closed angle mechanically in PACe when medical treatment fails to control the lOP. It is effective in situations when laser iridotomy cannot be performed because of corneal oedema secondary to high lOP. A ring of contraction burns (low power, long duration and large spot size) is placed on all 3600 of the peripheral iris to contract the iris stroma near the angle. The contraction pulls the iris tissue away from the trabecular meshwork thus opening up the angle and lowering the lOP. This will allow the cornea to become clear and inflammation to subside before definitive treatment is performed.1O-13 The usual practice is to perform ALPI 3-6 h after maximal medications fail to controHhe IOPY The current practice of using ALPI only after maximal anti-glaucomatous medications fail may not be optimal. For those who fail to respond to the medical treatment, increased optic nerve damage and permanent closure of the angle with damage to the trabecular meshwork may result from the prolonged elevated IOP.14 Moreover, whether they respond to the medical treatment or not, patients may also suffer from the side effects of the systemic medications.
For the above reasons we have undertaken a preliminary study in which P ACG patients were treated with topical anti-glaucomatous therapy and immediate ALPI, in the conventional 3600 manner.15 ALPl without the use of systemic anti-glaucomatous therapy in P ACG patients with a duration of attack � 48 h was found to be both effective and safe in controlling the lOP. Corneal clarity returned early, facilitating the definitive treatment of laser iridotomy without delay.
We have experienced uncooperative patients and patients who developed nausea and volniting during the laser treatment. Under those circumstances, less than 3600 of the peripheral iris were treated. However, the lOPs were still successfully lowered to safe levels. We therefore postulate that treatment of 3600 of the peripheral iris may not be needed to lower the lOP. As long as the effective burns successfully open up part of the angle, the vicious cycle will be broken and pupillary block will be relieved. Moreover, fewer laser burns should decrease the chance of laser-related complications. There are conditions in which 3600 ALPI may not be feasible, for example in uncooperative patients, or patients with media opacities such as corneal opacities, pannus and pterygium obscuring part of the peripheral iris. The question of whether one should still attempt ALPl on such patients remains to be answered. There has been no documentation in the literature as to how much ALPl is enough to abort an attack of P ACG. This study aimed at evaluating the effectiveness and safety of 1800 ALP!.
Materials and methods
All patients were recruited from the Eye Unit, Prince of Wales Hospital. Inclusion criteria were: (1) a first episode of P ACG; (2) lOP;;. 40 mmHg (by applanation tonometry); (3) duration of attack � 48 h; (4) no other previous ophthalmic disorders that may have had a persistent effect on the structure or function of the drainage angle. Exclusion criteria were: (1) anti glaucomatous treatment prior to the patient's presentation to the authors; (2) media opacities that obstructed laser access to more than 1800 of the peripheral iris. The study period was from September 1997 to April 1998.
Informed consent was obtained from each participating patient. The involved eye of these patients was given 1 drop of 4% pilocarpine and 1 drop of 0.5% timolol. Neither carbonic anhydrase inhibitors nor hyperosmotic agents were used. ALPI was performed under topical anaesthesia with amethocaine eye drops (1 %). The Alcon Biophysic laser machine (Model 532; Alcon Laboratories, Fort Worth, TX) was used. The laser was initially set at an energy level of 300 m W. The duration of each laser pulse was 0.3 s, with a spot size of 500 fLm. The laser beam was focused onto the peripheral iris as close to the limbus as possible with the Abraham laser iridotomy contact lens (Ocular Instruments, Bellevue, WA). A 1800 segment of the peripheral iris was treated. The site most amenable to laser treatment was chosen. If no part of the iris was obscured, the inferior 1800 of the peripheral iris was treated. The end-point was reached when localised iris contraction at the treated area became visible. The laser energy level was reduced if any of the following were observed: (1) charring of the iris; (2) formation of gas bubbles; (3) production of a 'pop', indicating a minute explosion. The laser energy level was increased if there was no contraction response from the iris. One drop of topical apraclonidine (1%) was given after ALPI as prophylaxis against the post-laser lOP spike.
lOP was measured by Goldmann applanation tonometry immediately before, and at IS, 30 and 60 min after ALP!. If the lOP remained above 22 mmHg at 60 lnin it was rechecked at 90 min after ALP!. The involved eye was given 1 drop of 1% pilocarpine 4 times a day, and 1 drop of 0.5% timolol twice a day, after ALPl until the definitive treatment of laser iridotomy was performed. Topical prednisolone acetate (1%) was also given six times a day for 7 days after ALP!. Patients were followed up for any complications arising from the laser procedure.
Results
Ten consecutive patients with their first acute P ACG and duration of attack � 48 h were recruited into the study. Pupillary block was clinically the mechanism underlying the acute P ACG in all patients. There were 6 men and 4 women, ranging in age from 63 to 83 years (mean 71.9 years) ( Table 1 ). All 10 patients were of Chinese ethnic origin, with dark brown irides. No patient had a previous history of glaucoma or other eye treatment.
The duration of attack prior to presentation, as determined by the onset of ocular pain and decreased vision of the affected eye, ranged from 2 to 48 h (mean 20.3 h). The visual acuity at presentation ranged from 20/100 to light perception (LP). Ninety per cent (9/10) of the patients had a visual acuity of 20/200 or less at the time of presentation. All patients had corneal oedema at presentation. All patients had a fixed, mid-dilated pupil of 4-6 mm (Table 1) .
At presentation, the lOP ranged from. 42 to 72 rrunHg (mean 57.9 ± 10.6 mmHg) ( Table 1) . Immediate ALPI was performed once the clinical diagnosis of P ACG was made. The laser contraction bums were placed in the far periphery in 1800 of the iris. The mean number of contraction bums placed was 77.0 (range 38-136 bums). The mean energy level was 376 m W (range 325-420 m W). The exposure time was 0.30 s and spot size used was 500 fLm in all patients (Table 1 ). All ALPls were completed within 10 min.
Fifteen minutes after ALPI the mean lOP dropped to a mean of 39.0 ± 10.9 mmHg (range 23-58 mmHg) ( Table  1 ). This represented a 32.6% reduction in mean lOP within 15 min after ALP!. Thirty minutes after ALPI the mean lOP was 28.3 ± 9.1 mmHg (range 15-45 mmHg) ( Table 1 ). This represented a further 27.4% reduction in lOP, compared with the lOP at 15 min after ALP!. This total reduction in lOP 30 min after ALPI was 51.1%. One hour after ALPI the mean lOP dropped to 20.4 ::!:
9.0 mmHg (range 8-38 mmHg) ( Table 1 ). In 70% (7/10) of the patients the lOP was � 18 mmHg, which was well within the normal limit. Patients 2, 3 and 4 had lOPs of 30, 29 and 38 mmHg respectively. At 1.5 h after ALPI the lOPs of patients 2, 3 and 4 dropped to 18, 20 and 20 mmHg, respectively (Table 1) . By 1 h after ALPI 8 of the 10 corneas had clarity re-established , allowing early laser iridotomy as definitive treatment. The corneas of patients 4 and 9 became clear by 2 h.
The visual acuity of the involved eye 1 day after ALPI ranged from 20/30 to light perception (LP), with 5 of the 10 patients having a visual acuity of 20/70 or better. Fig. 1 shows the lOP profiles in the 10 patients recruited into this study.
Discussion
ALPI has a well-establishe d role in the management of patients with P ACG resistant to conventional topical and systemic anti-glaucoma tous medications.1O -i3 To avoid the potential side effects of systemic medications, which can be particularly serious in frail elderly patients, and also the unnecessary delay in the control of the lOP, we have previously proposed applying ALPI, alongside topical anti-glaucoma tous medications, as the first-line treatment for P ACG, without the use of systemic medications from the start.15 A preliminary study suggested that this alternative regime is safe and as effective as systemic medications in lowering the lOP, but without the potentially serious side effects.
ALPI is traditionally applied to all 3600 of the peripheral iris. We have, however, come across patients in whom it was not possible to complete ALPI in all 3600 of the peripheral iris. These were mostly patients who were not able to cooperate or to tolerate the procedure right through to the end. It was noted that in many of 80 �--------------------------------------------------------- 
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Time course in relation to ALP! (minutes) Fig. 1 . Profile of intraocular pressure (lOP) changes before and after argon laser peripheral iridoplasty (ALPI) in 10 patients.
these patients we were able promptly to lower the lOP despite the fact that ALPI had been applied to only 180°, or sometimes even less, of the iris. We therefore hypothesised that it may not be necessary to complete 360° ALPI to achieve the reversal of an acute P ACG attack, and that perhaps ALPI over 180° may be sufficient to abort an attack. It has not been documented in the scientific literature how much of the peripheral iris needs to be treated by ALPI to achieve prompt pressure control in PACG. In our experience it is not always feasible to apply ALPI in all 360° of the peripheral iris. For example, a pannus encroaching onto the peripheral cornea can obscure part of the peripheral iris, as can a pterygium. Alternatively, any corneal scars, resulting from inflammatory conditions, or from mechanical or chemical trauma, can also obstruct laser access to the peripheral iris.
In this study we deliberately applied ALPI to only half the peripheral iris (180°) in 10 consecutive patients with their first attack of P ACG. This pilot study was aimed at determining whether limited ALPI to only half the peripheral iris would be sufficient to abort an attack of P ACG. The study was an attempt to address the question of whether one should apply immediate ALPI to those P ACG patients with only part of their peripheral iris amenable to laser treatment.
This study has relevance also to patients with no anterior segment media opacities. Anterior segment laser procedures carry risks, even though the risks associated with immediate ALPI for P ACG may be small. The basic principle remains that one should apply as little laser energy as possible to achieve the targeted end-point.
Theoretically the more laser burns that are applied to the iris, the more the inflammation and the higher the risk of corneal bum and lens injury. If 180° treatment is equally effective, we may not need or want to treat 360° From this study it appears that 180° ALPI may be effective in the control of lOP in P ACG. It is able to lower the lOP from an initial, dangerous level of 57.9 mmHg (mean) to a much safer level of 20 mmHg or below in 70% of P ACG patients in 60 mm. This safer level of lOP was achieved in 100% of patients after 90 min. Topical apraclonidine was used in this study as prophylaxis against the post-laser lOP spike, and it may have contributed to the lOP reduction. in addition to the effect of ALP!. In all patients their corneal oedema cleared in 2 h, allowing laser peripheral iridotomy to be performed. None of the patients in this study suffered any complications arising from the laser procedure. Immediate AL PI appeared to be effective and safe, and free from the potential systemic side effects of the conventional systemic medications. We suggest that immediate AL PI may be considered as the first-line treatment of P ACG. It is of particular value in those patients who are at risk from systemic complications. From the results of this study we do not believe that media opacities obstructing laser access to part of the peripheral iris, or lack of patient cooperation, should be absolute contraindications to AL P!. We would like to propose a large-scale prospective clinical trial to identify the minimum laser treatment required to abort an attack of PACG.
